☆ 4.8 Article

Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial

NATURE COMMUNICATIONS (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

David Simon et al.

Summary: The study found that a third vaccination in IMID patients who did not respond to standard vaccination can induce protective immunity. Seroconversion and neutralising activity were higher in non-RTX patients compared to RTX-treated patients. T cell responses did not significantly impact vaccination efficacy.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Michael Bonelli et al.

Summary: This study found that an additional booster vaccination is effective and safe for non-seroconverted patients after receiving conventional COVID-19 vaccination. Both vector and mRNA vaccines have comparable efficacy in enhancing humoral and cellular immune response, which is particularly important for immunosuppressed patients.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals

Vivek Naranbhai et al.

Summary: This study shows that T cell responses to the Omicron variant are largely preserved in individuals with prior infection, vaccination, or booster vaccination, although a subset of individuals may experience a reduction in T cell reactivity to the Omicron spike protein.

CELL (2022)

Add to Collection

Article Surgery

SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications

Gianluca Russo et al.

Summary: Solid organ transplant patients are at higher risk for poor COVID-19-related outcomes and have been prioritized for vaccination. A study in Italy assessed the safety and efficacy of the BNT162b2 mRNA vaccine in 82 kidney transplant patients, finding a 52.4% seroprevalence after 43 days post-vaccination with no impact on rejection or graft function. Age over 60 and use of anti-metabolites were associated with lack of seroconversion following vaccination. Further large studies are needed to determine the best vaccination strategy for transplanted patients.

CLINICAL TRANSPLANTATION (2022)

Add to Collection

Article Urology & Nephrology

Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients

Diana Rodriguez-Espinosa et al.

Summary: This observational study assesses the clinical protection provided by mRNA vaccines in kidney transplant recipients and haemodialysis patients. The study finds that kidney transplant recipients have a higher risk of hospital admission and may require booster doses, while haemodialysis patients exhibit adequate clinical response to vaccination for up to four months.

JOURNAL OF NEPHROLOGY (2022)

Add to Collection

Article Clinical Neurology

Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Carla Tortorella et al.

Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.

NEUROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Homologous and Heterologous Covid-19 Booster Vaccinations

R. L. Atmar et al.

Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients A Randomized Clinical Trial

Roman Reindl-Schwaighofer et al.

Summary: Less than 50% of kidney transplant recipients developed antibodies against the SARS-CoV-2 spike protein after 2 doses of an mRNA vaccine. A third dose of either mRNA or vector vaccine increased antibody response in 39% of KTRs without prior immune response, but neutralizing antibodies and T-cell response remained low. Triple immunosuppression, longer time after transplant, and torque teno virus plasma levels were associated with vaccine response. Local pain was higher with mRNA vaccine, but systemic symptoms were similar between groups.

JAMA INTERNAL MEDICINE (2022)

Add to Collection

Article Immunology

SARS-CoV-2 Spike-Specific CD4+T Cell Response Is Conserved Against Variants of Concern, Including Omicron

Alessio Mazzoni et al.

Summary: This study found that previous Alpha variant infection can reactivate CD4+ T cell memory, and most Spike-specific CD4+ T cell responses are conserved against SARS-CoV-2 variants, providing an effective defense against the development of severe COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

SARS Cov-2 vaccination induces de novo donor-specific HLA antibodies in a renal transplant patient on waiting list: A case report

Ahmad Abu-Khader et al.

Summary: The ability of COVID-19 vaccination to induce anti-HLA antibodies in renal transplant candidates is not well studied. This case study highlights the potential formation of these antibodies after vaccination, which could impact future transplantability for patients on waitlists.

HLA (2022)

Add to Collection

Article Oncology

Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations

Maximilian J. Mair et al.

Summary: This study found that cancer patients can develop anti-SARS-CoV-2 antibodies after vaccination, but at lower levels compared to healthcare workers. Further research on vaccination effects in cancer patients is needed.

JAMA ONCOLOGY (2022)

Add to Collection

Letter Rheumatology

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series

Caoilfhionn M. Connolly et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

T cell responses to SARS-CoV-2 spike cross-recognize Omicron

Roanne Keeton et al.

Summary: Despite reduced neutralizing antibody activity, T cell responses induced by vaccination or infection can cross-recognize the Omicron variant and provide protection.

NATURE (2022)

Add to Collection

Article Immunology

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis

Chiara Farroni et al.

Summary: This study assessed the kinetics of humoral and cell-mediated responses in rheumatoid arthritis patients treated with different immunosuppressive therapies after receiving SARS-CoV-2 vaccination. The results showed a reduction in antibody titers after 6 months, although they were still detectable in a majority of patients. B-cell and T-cell responses were also weakened.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals

Lorenzo De Marco et al.

Summary: This cohort study in Italy showed that the SARS-CoV-2 Omicron variant was recognized by the cellular component of the immune system in immunized adults, despite mutations in the spike protein. It is reasonable to assume that protection from hospitalization and severe disease will be maintained.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

Matthias B. Moor et al.

Summary: The study investigated immune responses to SARS-CoV-2 mRNA vaccines in patients receiving CD20-targeted B-cell-depleting therapies. Results showed blunted immune responses in these patients, indicating potential challenges in vaccination strategies for this population.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Jose Jesus Broseta et al.

Summary: This study evaluated the humoral and cellular responses to mRNA SARS-CoV-2 vaccines in patients with kidney failure receiving maintenance dialysis. Results showed that a high proportion of patients developed humoral and cellular immune responses after vaccination, but older age and immunosuppressive treatment were associated with lower antibody levels.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Urology & Nephrology

B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients

Eva Schrezenmeier et al.

Summary: The study found that 36% of kidney transplant recipients showed seroconversion after receiving a third dose of vaccine, highlighting the need for individual humoral monitoring and continued efforts to adapt vaccination protocols for immunosuppressed individuals. The quantitative and qualitative changes in cellular immunity associated with seroconversion emphasize the importance of modified vaccination approaches for this at-risk group.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Surgery

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Ayelet Grupper et al.

Summary: Only 37.5% of transplant recipients developed a positive immune response to the Pfizer vaccine, with lower antibody levels, and factors associated with null immune response include older age, high-dose corticosteroids use, triple immunosuppression maintenance, and regimen with mycophenolate.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Immunology

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine

Annalisa Ciabattini et al.

Summary: The study found that spike-specific antibodies and memory B cells still persisted up to 6 months after BNT162b2 vaccine administration, indicating a lasting immune protection against SARS-CoV-2 virus.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Infectious Diseases

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

Alessandra D'Abramo et al.

Summary: Prolonged B-cell depletion caused by anti-CD20 therapy impairs the adaptive immune response, leading to severe manifestations during COVID-19. Two patients under anti-CD20 therapy experienced prolonged and severe COVID-19 but were successfully treated with mAbs targeting the SARS-CoV-2 spike proteins.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Transplantation

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Benedikt Simon et al.

Summary: HD patients had significantly lower anti-SARS-CoV-2 S antibody titres compared to controls 21 days after vaccination. The HD group experienced fewer adverse events than the control group. There was no correlation between the antibody response to Hepatitis B vaccination and the SARS-CoV-2 vaccine.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Surgery

Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients

Tina Schmidt et al.

Summary: This study found that solid organ transplant recipients had lower levels of SARS-CoV-2-specific antibodies and T cells compared to controls after homologous or heterologous vaccination. However, heterologous vaccination showed promise in improving immune responses in transplant recipients, with higher induction of antibodies and CD4 T cells.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Surgery

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

David Cucchiari et al.

Summary: The study on 148 kidney transplant recipients showed that the mRNA SARS-CoV-2 vaccine elicited either cellular or humoral response in 65.0% of the patients. Approximately 20.9% of patients were considered to have prior immunization against SARS-CoV-2, while 79.1% were deemed naïve to the virus.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Medicine, General & Internal

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

William A. Werbel et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients

Rene Schramm et al.

Summary: Ninety percent of cardiothoracic transplant patients showed no detectable immune response three weeks after receiving two doses of the BNT162b2 vaccine, in sharp contrast to the robust immune response seen in the control group.

CLINICAL RESEARCH IN CARDIOLOGY (2021)

Add to Collection

Letter Urology & Nephrology

A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse

Timm H. Westhoff et al.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

Add to Collection

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Emma Pritchard et al.

Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients

Caroline X. Qin et al.

TRANSPLANTATION (2021)

Add to Collection

Article Immunology

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

Andrea Picchianti-Diamanti et al.

Summary: In RA patients, the majority developed antibody-specific and whole-blood spike-specific T-cell responses following COVID-19 mRNA vaccine administration, with stable disease activity. The magnitude of these specific responses depended on the immunosuppressive therapy administered.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

SARS-CoV-2 variants of concern partially escape humoral but not T- cell responses in COVID-19 convalescent donors and vaccinees

Daryl Geers et al.

Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.